DOCKF.US Beyond Medical Technologies Inc
- Market cap
- USD 2.42M
- P/E
- -
- P/B
- 20.06x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is DOCKF.US undervalued?
Graham numberThe Graham number of Beyond Medical Technologies Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beyond Medical Technologies Inc fundamental analysis
No fundamental analysis for Beyond Medical Technologies Inc yet.
Beyond Medical Technologies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beyond Medical Technologies Inc
Republic Technologies Inc. provides Ethereum-based technology services. The company develops Validity Network, an attestation platform that provides cryptographically secure and tamper-resistant assurances of data integrity by anchoring data commitments directly onto the Ethereum blockchain. It also engages in synthetic mining and validator infrastructure operations. The company was formerly known as Beyond Medical Technologies Inc. and changed its name to Republic Technolog…
Full company profileBeyond Medical Technologies Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beyond Medical Technologies Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 209K | 943K | 0.00 | 0.00 | 0.00 | 11.5K | -30.2K |
| Gross Profit | - | - | - | 0.00 | 24.7K | -250K | -225K | - | - | - | - |
| Operating Income | - | -2.02M | -2.93M | -2.80M | -2.08M | -2.06M | -837K | -548K | -439K | -1.99M | -1.58M |
| EBITDA | - | -2.02M | -2.91M | -2.68M | -1.93M | -2.73M | -837K | -548K | -366K | -2.09M | -12.8M |
| Net Income | - | -8.44M | -3.21M | -5.37M | -6.52M | -2.91M | -1.40M | -596K | -286K | -2.68M | -15.7M |
| EPS | - | -0.28 | -0.08 | -0.14 | -0.12 | -0.04 | -0.18 | -0.08 | -0.04 | -0.08 | -0.48 |
| Balance Sheet | |||||||||||
| Total Assets | - | 5.78M | 8.50M | 3.84M | 1.84M | 1.95M | 608K | 95.6K | 13.8K | 15.9M | 7.31M |
| Total Liabilities | - | 119K | 284K | 306K | 362K | 413K | 347K | 430K | 634K | 15.7M | 11.8M |
| Shareholders' Equity | - | 5.66M | 8.22M | 3.54M | 1.48M | 1.54M | 261K | -335K | -621K | 137K | -4.48M |
| Cash & Short-term Investments | - | 4.58M | 3.08M | 2.78M | 624K | 1.43M | 537K | 64.1K | 13.2K | 2.76M | 223K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -211K | -1.36M | -1.86M | -2.40M | -1.83M | -1.40M | -947K | -527K | -110K | -1.70M | -3.50M |
| Capital Expenditure | 64.2K | 37.6K | 1.59M | 1.18M | 234K | 68.0K | 0.00 | 0.00 | 0.00 | 0.00 | 502K |
| Free Cash Flow | - | -1.39M | -2.06M | -2.43M | -2.07M | -1.47M | -947K | -527K | -110K | -1.70M | -4.01M |
| Ratios | |||||||||||
| ROE | - | -149.0% | -39.0% | -151.7% | -440.0% | -189.2% | -536.2% | - | - | -1,961.4% | - |
| ROA | - | -145.9% | -37.7% | -139.6% | -353.7% | -149.2% | -230.3% | -623.2% | -2,071.3% | -16.9% | -214.7% |
| Net Profit Margin | - | - | - | - | -3,125.2% | -308.7% | - | - | - | -23,355.0% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Beyond Medical Technologies Inc dividends
Beyond Medical Technologies Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Dec 30, 2022.
Who owns Beyond Medical Technologies Inc
- Insiders 48.95%
- Institutions 0.00%
- Public & others 51.05%
- Shares outstanding 32.8M
- Free float 16.7M
Beyond Medical Technologies Inc company profile
- Company name
- Beyond Medical Technologies Inc
- Ticker
- DOCKF.US
- Exchange
- USA Stocks
- Sector
- Industrials
- Industry
- Machinery
- Fiscal year end
- December
- Address
- 1111 West Hastings Street, Vancouver, BC, Canada, V6E 2J3
- Phone
- 778-200-4124
- Website
- republictech.io
About Beyond Medical Technologies Inc
Republic Technologies Inc. provides Ethereum-based technology services. The company develops Validity Network, an attestation platform that provides cryptographically secure and tamper-resistant assurances of data integrity by anchoring data commitments directly onto the Ethereum blockchain. It also engages in synthetic mining and validator infrastructure operations. The company was formerly known as Beyond Medical Technologies Inc. and changed its name to Republic Technologies Inc. in July 2025. Republic Technologies Inc. is based in Vancouver, Canada.
Beyond Medical Technologies Inc management
3- Mr. Daniel LiuInterim CFO, CEO & Director
- Ms. Litong CaoCOO & Director
- Ms. Karen LauristonVice President of Corporate Communications & Investor, Community and Government Relations